Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1756-8722
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies ; volume:10 ; number:1 ; day:11 ; month:1 ; year:2017 ; pages:1-4 ; date:12.2017
Journal of hematology & oncology ; 10, Heft 1 (11.1.2017), 1-4, 12.2017
- Urheber
-
Schönfeld, Kurt
- Beteiligte Personen und Organisationen
-
Zuber, Chantal
Pinkas, Jan
Häder, Thomas
Bernöster, Katrin
Uherek, Christoph
SpringerLink (Online service)
- DOI
-
10.1186/s13045-016-0380-0
- URN
-
urn:nbn:de:101:1-2018083108361490926608
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:31 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Schönfeld, Kurt
- Zuber, Chantal
- Pinkas, Jan
- Häder, Thomas
- Bernöster, Katrin
- Uherek, Christoph
- SpringerLink (Online service)
Ähnliche Objekte (12)
Multiple myeloma
PDI inhibitor LTI6426 enhances panobinostat efficacy in preclinical models of multiple myeloma
Induction of activin A with lenalidomide in multiple myeloma : preclinical rationale for combination with the activin A inhibitor ACE-011.
Modulating glycosphingolipid metabolism and autophagy improves outcomes in pre-clinical models of myeloma bone disease
Therapeutic potential of cladribine in combination with STAT3 inhibitor against multiple myeloma
Geranylgeranyl diphosphate synthase inhibitor and proteasome inhibitor combination therapy in multiple myeloma
Leveraging multi-way interactions for systematic prediction of pre-clinical drug combination effects
Imaging of Multiple Myeloma
Potential value of pre-planned imaging of bone disease in multiple myeloma
Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma
Synergistic effect of FOXM1 and BCL-2 inhibition in a preclinical treatment study on multiple myeloma
Components of metabolic syndrome in patients with multiple myeloma and smoldering multiple myeloma
Multiple myeloma
PDI inhibitor LTI6426 enhances panobinostat efficacy in preclinical models of multiple myeloma
Induction of activin A with lenalidomide in multiple myeloma : preclinical rationale for combination with the activin A inhibitor ACE-011.
Modulating glycosphingolipid metabolism and autophagy improves outcomes in pre-clinical models of myeloma bone disease
Therapeutic potential of cladribine in combination with STAT3 inhibitor against multiple myeloma
Geranylgeranyl diphosphate synthase inhibitor and proteasome inhibitor combination therapy in multiple myeloma
Leveraging multi-way interactions for systematic prediction of pre-clinical drug combination effects
Imaging of Multiple Myeloma
Potential value of pre-planned imaging of bone disease in multiple myeloma
Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma
Synergistic effect of FOXM1 and BCL-2 inhibition in a preclinical treatment study on multiple myeloma
Components of metabolic syndrome in patients with multiple myeloma and smoldering multiple myeloma
Multiple myeloma
PDI inhibitor LTI6426 enhances panobinostat efficacy in preclinical models of multiple myeloma
Induction of activin A with lenalidomide in multiple myeloma : preclinical rationale for combination with the activin A inhibitor ACE-011.
Modulating glycosphingolipid metabolism and autophagy improves outcomes in pre-clinical models of myeloma bone disease
Therapeutic potential of cladribine in combination with STAT3 inhibitor against multiple myeloma
Geranylgeranyl diphosphate synthase inhibitor and proteasome inhibitor combination therapy in multiple myeloma
Leveraging multi-way interactions for systematic prediction of pre-clinical drug combination effects
Imaging of Multiple Myeloma
Potential value of pre-planned imaging of bone disease in multiple myeloma
Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma
Synergistic effect of FOXM1 and BCL-2 inhibition in a preclinical treatment study on multiple myeloma